RESUMEN
Ghrelin, a natural GH secretagogue (GHS) acylated peptide, and cortistatin (CST), a natural SRIF-like peptide, interfere with neoplastic growth in different cancers. We tested forty-one lung carcinomas and the H345 small cell lung carcinoma (SCLC) cell line by RT-PCR to investigate the presence of ghrelin and CST and related receptors, including type 1a GHS receptor (GHS-R1a), all SRIF-receptor subtypes (sst 1-5) and MRGX2. Moreover, the presence of ghrelin and CST peptides was studied in both tumors and H345 cells. Ghrelin and CST mRNA were present in the majority of tested tumors, but ghrelin and CST proteins were revealed only in tumors with a neuroendocrine phenotype. All the receptors mRNA had a heterogeneous expression without correlation between ghrelin (or CST) and their receptor distribution. All the transcripts, but not GHS-R1a, were expressed in H345 cells. However, ghrelin and desacyl ghrelin induced in vitro a dose-dependent inhibition on the H345 cell proliferation and increased apoptosis. Conversely, neither CST nor SRIF affected H345 cell growth, despite the presence of their specific receptors. The anti-proliferative and the pro-apoptotic effects of ghrelin were consistent with binding experiments on H345 cell, where either acylated or des-acylated ghrelin recognized a common binding site. In conclusion, the present study indicates that: a) ghrelin and CST mRNAs are expressed in lung cancers, although some neuroendocrine tumors contain detectable amounts of the peptides; b) GHSR-1a mRNA is present exclusively in neuroendocrine tumors, whereas MRGX2 mRNA (but not peptide) is expressed in all histological types; c) both ghrelin forms inhibit H345 cell proliferation, both directly and enhancing apoptosis, despite the absence of GHS-R1a, whereas CST and its receptors do not interfere with cell growth.
Asunto(s)
Carcinoma de Células Pequeñas/metabolismo , Neoplasias Pulmonares/metabolismo , Neuropéptidos/metabolismo , Hormonas Peptídicas/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Receptores de Somatostatina/metabolismo , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Membrana Celular/metabolismo , Proliferación Celular/efectos de los fármacos , Expresión Génica , Ghrelina , Humanos , Proteínas del Tejido Nervioso/metabolismo , Neuropéptidos/farmacología , Hormonas Peptídicas/farmacología , Péptidos Cíclicos/farmacología , Unión Proteica , Receptores de Ghrelina , Receptores de Neuropéptido/metabolismo , Somatostatina/análogos & derivados , Somatostatina/farmacologíaRESUMEN
The family of GH secretagogues (GHS) includes peptidyl (hexarelin) and nonpeptidyl (MK 0677) molecules possessing specific receptors in the brain, pituitary, and thyroid. GHS receptor subtypes have also been identified in the heart; and a gastric-derived peptide, named ghrelin, has recently been proposed as a natural ligand. Our aim was to investigate the presence of GHS receptors in a wide range of human tissues, by radioreceptor assay with [125I]Tyr-Ala-hexarelin. GHS receptors were detected mainly in the myocardium, but they were also present (in order of decreasing binding activity) in adrenal, gonads, arteries, lung, liver, skeletal muscle, kidney, pituitary, thyroid, adipose tissue, veins, uterus, skin, and lymphnode. In contrast, negligible binding was found in parathyroid, pancreas, placenta, mammary gland, prostate, salivary gland, stomach, colon, and spleen. Hexarelin, MK 0677, and human ghrelin completely displaced the radioligand from binding sites of endocrine tissues, but MK 0677 and ghrelin were less potent than hexarelin. In nonendocrine tissues, both MK 0677 and ghrelin were inactive in displacement of [125I]Tyr-Ala-hexarelin, whereas hexarelin was as active as a displacing agent in endocrine tissues. This study provides the first detailed analysis of the tissue localization of GHS receptors and suggests that a still unknown receptor subtype, specific for peptidyl GHS, may exist in the heart and in other tissues.
Asunto(s)
Sustancias de Crecimiento/metabolismo , Hormona de Crecimiento Humana/metabolismo , Indoles/metabolismo , Oligopéptidos/metabolismo , Hormonas Peptídicas , Receptores de Superficie Celular/metabolismo , Compuestos de Espiro/metabolismo , Adulto , Sitios de Unión , Unión Competitiva/efectos de los fármacos , Femenino , Ghrelina , Humanos , Radioisótopos de Yodo , Cinética , Masculino , Membranas/efectos de los fármacos , Membranas/metabolismo , Persona de Mediana Edad , Péptidos/metabolismo , Ensayo de Unión Radioligante , Receptores de Superficie Celular/efectos de los fármacos , Distribución TisularRESUMEN
The family of GH secretagogues (GHS) includes synthetic peptidyl (hexarelin) and nonpeptidyl (MK-0677) molecules possessing specific receptors in the pituitary and central nervous system as well as in peripheral tissues, including the heart and some endocrine organs. A gastric-derived peptide, named ghrelin, has recently been proposed as the natural ligand of the GHS receptors (GHS-Rs). The presence of specific GHS-Rs has now been investigated in nontumoral and neoplastic human breast tissue using a radioiodinated peptidyl GHS ([(125)I]-Tyr-Ala-hexarelin) as ligand. Specific binding sites for GHS were detected in membranes from several types of breast carcinomas, whereas a negligible binding was found in fibroadenomas and mammary parenchyma. The highest binding activity was found in well-differentiated (G1) invasive breast carcinomas and was progressively reduced in moderately (G2) to poorly (G3) differentiated tumors. [(125)I]-Tyr-Ala-hexarelin bound to tumor membranes was displaced by different unlabeled GHS such as hexarelin, Tyr-Ala-hexarelin, human ghrelin, and MK-0677 as well as by desoctanoyl-ghrelin and hexarelin derivative EP-80317, which are devoid of GH-releasing properties in vivo. In contrast, no competition was seen between radiolabeled Tyr-Ala-hexarelin and some peptides (CRF and insulin-like growth factor I) structurally and functionally unrelated to hexarelin or when GHRH and SRIF were tested in the displacement studies. The presence of specific GHS binding sites was also demonstrated in three different human breast carcinoma cell lines (MCF7, T47D, and MDA-MB231), in which, surprisingly, no messenger RNA for GHS-R1a was demonstrated by RT-PCR. In these cell lines, ghrelin (as well as hexarelin, MK-0677, EP-80317, and even desoctanoyl ghrelin) caused a significant inhibition of cell proliferation at concentrations close to their binding affinity. In conclusion, this study provides the first demonstration of specific GHS binding sites, other than GHS-R1, in breast cancer. These receptors probably mediate growth inhibitory effects on breast carcinoma cells in vitro.
Asunto(s)
Neoplasias de la Mama/metabolismo , Carcinoma/metabolismo , Hormonas Peptídicas , Péptidos/metabolismo , Receptores de Superficie Celular/metabolismo , Mama/citología , Mama/metabolismo , Neoplasias de la Mama/patología , Carcinoma/patología , Línea Celular , Femenino , Fibroadenoma/metabolismo , Fibroadenoma/patología , Ghrelina , Hormona del Crecimiento/metabolismo , Humanos , Indoles/metabolismo , Persona de Mediana Edad , Oligopéptidos/metabolismo , Valores de Referencia , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Compuestos de Espiro/metabolismoRESUMEN
Sixty cerebral meningioma specimens obtained at surgery from 34 female and 26 male patients were examined for the presence of prolactin (PRL) receptors. These were compared with normal arachnoid tissue from which these tumours arise. PRL receptors were detected in 61.7% of meningiomas whereas no PRL binding was found in samples of normal arachnoid tissue. No relationship was found when sex or histological findings were compared with the presence of PRL receptors. Receptor-positive tumours had saturable and high-affinity (Kd, 4.8 +/- 0.5 ng/ml) receptors with hormonal specificity for human PRL (hPRL) resembling that of other target tissues of PRL in man. The biological role of these receptors was investigated in primary cell cultures derived from meningioma tissue characterized for PRL receptor. When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. The PRL concentrations required to produce a half-maximal effect ranged from 11 to 20 ng/ml and were quite close to the dissociation constant (Kd) of binding of PRL to its receptors. PRL also caused an increase of cell number compared with control with a significant effect after 3 and 4 days of culture. In conclusion, these findings indicate that a large number of human meningiomas express specific and functional receptors for PRL which are involved in mediating its proliferative effects.
Asunto(s)
Neoplasias Meníngeas/química , Meningioma/química , Receptores de Prolactina/análisis , Adulto , Anciano , Aracnoides/química , División Celular , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Masculino , Neoplasias Meníngeas/metabolismo , Neoplasias Meníngeas/patología , Meningioma/metabolismo , Meningioma/patología , Persona de Mediana Edad , Prolactina/metabolismo , Prolactina/farmacología , Unión Proteica , Receptores de Prolactina/metabolismo , Células Tumorales Cultivadas/metabolismo , Células Tumorales Cultivadas/patologíaRESUMEN
The presence of specific receptors for synthetic growth hormone secretagogues (GHSs) has been investigated in non-tumoral and neoplastic human thyroid tissue using a radio-iodinated peptidyl GHS ((125)I-labelled Tyr-Ala-hexarelin) as ligand. Specific binding sites for Tyr-Ala-hexarelin were detected in membranes from non-tumoral and follicular-derived neoplastic thyroid tissue, but not in thyroid tumours (medullary carcinomas) of parafollicular (C cell) origin. The binding activity was greatest in well differentiated neoplasms (papillary and follicular carcinomas), followed by poorly differentiated carcinomas, non-tumoral thyroid parenchyma, follicular adenomas and anaplastic carcinomas. Both peptidyl (Tyr-Ala-hexarelin, hexarelin, growth hormone releasing peptide (GHRP6) and non-peptidyl (MK 0677) GHSs completely displaced the radioligand from binding sites of non-tumoral thyroid gland, but MK 0677 was significantly less potent. The IC(50) values were (1. 9+/-0.3)x10(-8) mol/l for Tyr-Ala-hexarelin, (2.1+/-0.2)x10(-8) mol/l for hexarelin, (2.4+/- 0.3)x10(-8) mol/l for GHRP6 and only (1. 5+/-0.4)x 10(-7) mol/l for MK 0677. Similar IC(50) values were found in neoplastic thyroid tissue. Scatchard analysis of the binding revealed a finite number of binding sites in non-tumoral (B(max): 1232+/-32 fmol/mg protein, n=3) and neoplastic (papillary carcinomas) thyroid tissue (B(max): 2483+/-380 fmol/mg protein, n=5), with dissociation constants (K(d)) of (3.8+/-0.3)x10(-9) and (4. 4+/-0.6)x 10(-9) mol/l, respectively. On the basis of this evidence, we investigated the effects of some GHS on the proliferation of three different human follicular thyroid carcinoma cell lines (NPA, WRO and ARO) in which the presence of specific GHS receptors was also demonstrated. Tyr-Ala-hexarelin, GHRP6 and MK 0677 were able to inhibit serum-stimulated [(3)H]thymidine incorporation in NPA cells at concentrations close to their binding affinity. These substances also caused a significant inhibition of cell proliferation, which was evident at the earliest time of treatment (24 h) in all the cell lines, and at the latest time (96 h) in NPA cells only. In conclusion, this paper confirms the existence of specific binding sites for GHS in normal thyroid tissue and demonstrates, for the first time, that these binding sites are present in papillary and follicular carcinomas, low in anaplastic carcinomas and absent in medullary carcinomas of the thyroid. This work also provides evidence of a growth-inhibitory effect of GHS on cell lines derived from follicular thyroid cancers.
Asunto(s)
Receptores de Somatotropina/metabolismo , Glándula Tiroides/metabolismo , Neoplasias de la Tiroides/metabolismo , Sitios de Unión , Humanos , Radioisótopos de Yodo/metabolismo , Oligopéptidos/metabolismo , Ensayo de Unión Radioligante , Neoplasias de la Tiroides/clasificación , Células Tumorales Cultivadas/metabolismoRESUMEN
In vitro studies have been performed to demonstrate and characterize specific binding sites for synthetic GH secretagogues (sGHS) on membranes from pituitary gland and different human brain regions. A binding assay for sGHS was established using a peptidyl sGHS (Tyr-Ala-hexarelin) which had been radioiodinated to high specific activity at the Tyr residue. Specific binding sites for 125I-labelled Tyr-Ala-hexarelin were detected mainly in membranes isolated from pituitary gland and hypothalamus, but they were also present in other brain areas such as choroid plexus, cerebral cortex, hippocampus and medulla oblongata with no sex-related differences. In contrast, negligible binding was found in the thalamus, striatum, substantia nigra, cerebellum and corpus callosum. The binding of 125I-labelled Tyr-Ala-hexarelin to membrane-binding sites is a saturable and reversible process, depending on incubation time and pH of the buffer. Scatchard analysis of the binding revealed a finite number of binding sites in the hypothalamus and pituitary gland with a dissociation constant (Kd) of (1.5 +/- 0.3) x 10(-9) and (2.1 +/- 0.4) x 10(-9) mol/l respectively. Receptor activity is sensitive to trypsin and phospholipase C digestion, suggesting that protein and phospholipids are essential for the binding of 125I-labelled Tyr-Ala-hexarelin. The binding of 125I-labelled Tyr-Ala-hexarelin to pituitary and hypothalamic membranes was displaced in a dose-dependent manner by different unlabelled synthetic peptidyl (Tyr-Ala-hexarelin, GHRP2, hexarelin, GHRP6) and non-peptidyl (MK 0677) sGHS. An inhibition of the specific binding was also observed when binding was performed in the presence of [D-Arg1-D-Phe5-D-Trp7,9-Leu11]-substance P, a substance P antagonist that has been found to inhibit GH release in response to sGHS. In contrast, no competition was observed in the presence of other neuropeptides (GHRH, somatostatin, galanin or Met-enkephalin) which have a known influence on GH release. In conclusion, the present data demonstrate that sGHS have specific receptors in human brain and pituitary gland and reinforce the hypothesis that these compounds could be the synthetic counterpart of an endogenous GH secretagogue involved in the neuroendocrine control of GH secretion and possibly in other central activities.
Asunto(s)
Encéfalo/metabolismo , Hormonas/metabolismo , Oligopéptidos/metabolismo , Hipófisis/metabolismo , Receptores de Neuropéptido/metabolismo , Receptores de Hormona Reguladora de Hormona Hipofisaria/metabolismo , Adulto , Anciano , Análisis de Varianza , Sitios de Unión , Femenino , Humanos , Concentración de Iones de Hidrógeno , Hipotálamo/metabolismo , Indoles/metabolismo , Radioisótopos de Yodo , Masculino , Persona de Mediana Edad , Unión Proteica , Ensayo de Unión Radioligante , Compuestos de Espiro/metabolismoRESUMEN
1. Old rats showed a significant decrease in the number of muscarinic M(1) receptors and a significant increase in membrane microviscosity in the striatum and hippocampus as compared to young animals. In contrast, no significant changes in the density of muscarinic M(2) receptors were observed with aging. 2. Chronic treatment of aged rats with L-alpha-glycerylphosphorylcholine (L-alpha-GPC) restored the number of M(1) receptors to levels found in the striatum and hippocampus from young animals. The same treatment to aged rats partially restored membrane microviscosity in both regions studied and hence increased membrane fluidity. 3. None of the major metabolites of L-alpha-GPC (choline, glycerophosphate or phosphorylcholine) was able to restore the number of striatal and hippocampal M(1) sites and membrane microviscosity of aged rats, neither did any of these treatments (including treatment with L-alpha-GPC) modify the level of M(1) receptors and microviscosity values in young rats.
Asunto(s)
Envejecimiento/efectos de los fármacos , Encéfalo/efectos de los fármacos , Membrana Celular/efectos de los fármacos , Glicerilfosforilcolina/farmacología , Receptores Muscarínicos/efectos de los fármacos , Animales , Relación Dosis-Respuesta a Droga , Masculino , Ratas , Ratas Sprague-Dawley , Viscosidad/efectos de los fármacosRESUMEN
1. PRL receptors in the hypothalamus and substantia nigra of aged rabbits (28-month-old) are significantly reduced in comparison with young rabbits (6-month-old). 2. Repeated treatments with BC-PS are able to gradually increase the PRL receptor number both in hypothalamus and nigra. However only after 30 days of treatment the binding reaches the mean values observed in young rabbits. 3. Aged rabbits showed an evident increase in PRL plasma levels in comparison with young animals. In BC-PS treated animals this increase was not more apparent. Moreover in young rabbits treated with BC-PS an evident decrease in basal PRL plasma levels was observed.
Asunto(s)
Encéfalo/crecimiento & desarrollo , Fosfatidilserinas/farmacología , Receptores de Prolactina/metabolismo , Glándulas Suprarrenales/crecimiento & desarrollo , Envejecimiento , Animales , Encéfalo/metabolismo , Plexo Coroideo/crecimiento & desarrollo , Femenino , Cinética , Liposomas , Hígado/crecimiento & desarrollo , Masculino , Especificidad de Órganos , Prolactina/metabolismo , Conejos , Receptores de Prolactina/efectos de los fármacosRESUMEN
Specific binding sites for prolactin (PRL) have been studied in human peripheral lymphocytes and erythrocytes of normal adult volunteers and of term cord bloods. In erythrocytes from healthy adult subjects of both sexes a very low specific binding of 125I-human PRL was found (0.24%), whereas a higher binding was found in term cord blood (1.1%). The binding was hormone specific, the binding capacity was 2.6 fmol/4 X 10(9) cells and the Kd was 3.4 X 10(-10) M. In lymphocytes of both adults and term cord bloods an evident specific binding was observed (male adults: 1.6%; female adults: 1.7%; cord blood: 1.8%). The binding was specific for lactogenic hormones and the binding capacity was 3.7 fmol/2 X 10(6) cells and the Kd was 3.9 X 10(-10) M. The presence of specific binding sites for PRL on human erythrocytes and lymphocytes could be used to study PRL binding on blood cells of patients in different physiological or pathological situations.
Asunto(s)
Eritrocitos/metabolismo , Linfocitos/metabolismo , Prolactina/metabolismo , Receptores de Prolactina/metabolismo , Adulto , Femenino , Sangre Fetal/metabolismo , Humanos , Recién Nacido , MasculinoRESUMEN
BACKGROUND: Meningiomas have been found to have receptors for several hormones, such as oestrogen, progesterone, somatostatin, dopamine and recently also for prolactin. METHODS: To investigate any possible role of prolactin in the growth of those tumours we detected the presence of prolactin-receptors (PRL-R) in 22 meningiomas and we correlated these data with PRL serum levels in patients before surgery. We also studied 13 patients with schwannomas and 7 with other cerebral tumours (4 glioblastomas, 2 ependymomas and 1 astrocytoma). RESULTS: Increased prolactin binding was present in 10 (45.4 percent;) meningiomas, 9 (69.2 percent;) schwannomas and in the patient with astrocytoma. The presence of high PRL levels was present in 6 (27.2 percent;) patients with meningiomas, 8 (61.5 percent;) with schwannomas and in 3 (42.8 percent;) with other tumours. No direct correlation was present between serum PRL levels and PRL binding in all groups. CONCLUSIONS: In conclusion we confirmed the presence of PRL receptors in patients with meningiomas and we have also shown the presence of PRL receptors also in schwannomas. Moreover increased serum PRL were shown in some patients with different tumours of nervous tissue before surgery. Our data could suggest that PRL might have a role in the growth of meningiomas and schwannomas.
Asunto(s)
Neoplasias Encefálicas/etiología , Hiperprolactinemia/complicaciones , Prolactina/sangre , Receptores de Prolactina/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Astrocitoma/etiología , Astrocitoma/metabolismo , Astrocitoma/fisiopatología , Sitios de Unión/fisiología , Neoplasias Encefálicas/metabolismo , Neoplasias Encefálicas/fisiopatología , Ependimoma/etiología , Ependimoma/metabolismo , Ependimoma/fisiopatología , Femenino , Glioblastoma/etiología , Glioblastoma/metabolismo , Glioblastoma/fisiopatología , Humanos , Hiperprolactinemia/fisiopatología , Masculino , Meningioma/etiología , Meningioma/metabolismo , Meningioma/fisiopatología , Persona de Mediana Edad , Neurilemoma/etiología , Neurilemoma/metabolismo , Neurilemoma/fisiopatología , Prolactina/metabolismoRESUMEN
Growth Hormone (GH)-releasing peptides (GHRPs) and their non peptidyl analogues are synthetic molecules which exhibit strong, dosedependent and reproducible GH-releasing activity but also significant PRL- and ACTH/cortisol-releasing effects. An influence of these compounds on food intake and sleep pattern has been also shown. The neuroendocrine activities of GHRPs are mediated by specific receptors subtypes that have been identified in the pituitary gland, hypothalamus and various extra-hypothalamic brain regions with (125)I-Tyr-Ala-hexarelin, an octapeptide of the GHRP family. In addition, GHRP receptors were also present in different peripheral tissues such as heart, adrenal, ovary, testis, lung and skeletal muscle, with a density significantly higher than that found in the hypothalamo-pituitary -system. A remarkable specific (125)I-Tyr-Ala-hexarelin binding was observed in the human cardiovascular system where the highest binding levels were detected in ventricles, followed by atria, aorta, coronaries, carotid, endocardium and vena cava. The binding of the radioligand to cardiac membranes was inhibited by unlabeled Tyr Ala hexare lin and hexarelin as well as by GHRP-6, GHRP-1 and GHRP-2 but not by MK-677, a non peptidyl GHRP analog. In other experiments on H9c2 myocytes, a fetal cardiomyocytes-derived cell line, specific GHRP binding was found and hexarelin showed an anti-apoptotic activity. On the other hand, in vivo studies in animals and in humans showed that GHRPs possess direct cardiotropic actions. In fact, hexarelin protects from ischemia-induced myocardial damage in aged and GH deficient rats while hexarelin shows a positive inotropic effect in normal subjects as well as in patients with GH deficiency. In conclusion, GHRPs possess extra--neuroendocrine biological activity and, particularly, show direct GH-independent cardiotropic effects.
Asunto(s)
Fenómenos Fisiológicos Cardiovasculares , Sistema Cardiovascular/efectos de los fármacos , Hormona Liberadora de Hormona del Crecimiento , Hormonas/farmacología , Animales , Femenino , Hormona de Crecimiento Humana/metabolismo , Humanos , Masculino , Oligopéptidos/farmacología , Receptores de Neuropéptido/fisiología , Receptores de Hormona Reguladora de Hormona Hipofisaria/fisiologíaRESUMEN
The binding of 125I-labeled rat prolactin (125I-rat PRL) to membranes from different regions of the rat brain was studied. Among these regions the hypothalamus showed the highest specific binding. Clearly detectable specific binding was also observed in substantia nigra, whereas it was very scanty in other brain regions. No significant sex differences in PRL binding to various brain regions were observed, except for hypothalamus where a higher binding was observed in female rats. The binding of 125I-rat PRL to hypothalamus from female rats was inhibited in a dose-dependent manner by both unlabeled rat and ovine PRL but not by several other polypeptide hormones. Scatchard analysis of the binding revealed the presence of the binding sites with low capacity and high affinity for rat ligand. Ovariectomy markedly decreased PRL binding in the hypothalamus; an even more pronounced decrease was found after hypophysectomy of female animals. A treatment with estradiol restored the PRL binding in the ovariectomized rats to above normal levels. These results of in vitro biochemical analysis together with the experimental modulation of hormonal status provide strong preliminary evidence for the presence of PRL binding sites in rat brain.
Asunto(s)
Encéfalo/metabolismo , Hipofisectomía , Ovariectomía , Receptores de Prolactina/metabolismo , Animales , Encéfalo/efectos de los fármacos , Membrana Celular/metabolismo , Estradiol/farmacología , Femenino , Hipotálamo/metabolismo , Radioisótopos de Yodo , Masculino , Prolactina/metabolismo , Ratas , Ratas Endogámicas , Caracteres Sexuales , Sustancia Negra/metabolismo , Distribución TisularRESUMEN
Modifications in prolactin and insulin specific binding in the mouse liver induced by repeated administrations of ovine prolactin (oPRL) or indomethacin were studied. oPRL induced a dose-dependent and reversible increase of prolactin binding capacity. No change was observed in dissociation constant values. Conversely, insulin binding capacity to the same liver membranes was not modified by the treatment with oPRL. The increase in the binding induced by oPRL was not influenced by cycloheximide and it is therefore not dependent on protein synthesis. On the other hand, indomethacin caused a dose-dependent inhibition of prolactin binding capacity, without changes in dissociation constant values. The inhibitory effect was specific since at the doses used insulin binding to the same membranes was not affected. When indomethacin treatment was associated to oPRL administration it was able to counteract the increase in binding capacity caused by oPRL, even at doses ineffective in reducing the binding in non oPRL-treated mice. Our results suggest that drug-induced membrane modifications can selectively affect prolactin receptors and could consequently modify the ability of the target cell to respond to different physiological or pharmacological situations.
Asunto(s)
Insulina/metabolismo , Hígado/metabolismo , Prolactina/metabolismo , Animales , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Cicloheximida/farmacología , Estradiol/farmacología , Indometacina/farmacología , Insulina/farmacología , Cinética , Hígado/efectos de los fármacos , Masculino , Ratones , Prolactina/farmacología , Receptor de Insulina/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Prolactina , Ovinos , Factores de TiempoRESUMEN
The binding of 125I-labeled ovine prolactin (125I-oPRL) to membranes from different brain regions of pigeon, rabbit, rat, pig, calf, horse, and ewe was studied. The hypothalamus from rabbit, pig, horse, and pigeon showed a low but specific binding for 125I-oPRL clearly different from the other brain regions examined (cortex and cerebellum), whereas in the brain from rat, calf, and ewe the binding was very small and quite uniform in the various regions. Also the membranes from choroid plexus of rabbit, pig, calf, and horse showed an evident specific binding for prolactin. The binding of 125I-oPRL to hypothalamus and choroid plexus membranes from rabbit and horse was inhibited in a dose-dependent manner by unlabeled oPRL and hGH but not by many other polypeptide hormones. Scatchard analysis of the binding revealed the presence of binding sites with low capacity and high affinity for ovine ligand.
Asunto(s)
Encéfalo/metabolismo , Prolactina/metabolismo , Receptores de Prolactina/metabolismo , Animales , Bovinos , Membrana Celular/metabolismo , Plexo Coroideo/metabolismo , Columbidae , Femenino , Caballos , Hipotálamo/metabolismo , Masculino , Conejos , Ratas , Ratas Endogámicas , Ovinos , Especificidad de la Especie , Porcinos , Distribución TisularRESUMEN
Insulin-like growth factor binding protein 3 (IGFBP-3) modulates the activity of IGF-I, which exerts antiapoptotic action upon the myocardiocyte. IGFBP-3 also exerts IGF-independent actions to inhibit cell growth and induce apoptosis, mediating the effects of several antiproliferative agents. We hypothesized that IGFBP-3 mediates cardiomyocyte apoptosis. IGFBP-3 expression was studied in H9c2 rat cardiac cells cultured in serum-deprived medium in the absence or presence of 1 microM doxorubicin during a 72 h time-span. To a greater degree than serum withdrawal, doxorubicin induced IGFBP-3 up-regulation that was time-dependent. IGFBP-3 mRNA levels positively correlated with the degree of apoptosis. Exogenous IGFBP-3 decreased cell viability and induced apoptosis in serum-starved cells exposed to doxorubicin. IGFBP-3 antisense oligonucleotides markedly decreased apoptosis induced by either serum withdrawal or doxorubicin. Binding studies revealed specific high-affinity sites for IGFBP-3 in H9c2 cardiomyocytes, with binding characteristics typical of receptor-ligand interactions. These findings indicate that IGFBP-3 could play proapoptotic action at the myocardial level and suggest a novel role for this protein in cardiovascular dysfunction.
Asunto(s)
Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Medio de Cultivo Libre de Suero/farmacología , Doxorrubicina/farmacología , Corazón/fisiología , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/fisiología , Animales , Sitios de Unión , Unión Competitiva , Línea Celular , Supervivencia Celular/efectos de los fármacos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/genética , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/farmacología , Miocardio/citología , Oligonucleótidos Antisentido/farmacología , RatasRESUMEN
OBJECTIVE: In the rat, prolactin receptors (PRL-R) have been identified in normal pituitary cells and in anterior pituitary tumours induced by oestradiol. No published data are available concerning PRL-R in the human pituitary. The aim of our study was therefore to detect the presence of PRL-R in the normal human pituitary gland and human pituitary adenomas. DESIGN: Evaluation of free and total PRL-R in the normal pituitary gland and different pituitary tumours characterized by immunocytochemical analysis. PATIENTS: Twenty-six unselected patients (14 M, 12 F) who underwent surgery for pituitary adenoma (3 prolactinomas, 4 GH-PRL adenomas, 5 GH adenomas, 1 ACTH adenoma, 9 glycoprotein and/or alpha-subunit adenomas, 4 null cells adenomas) were studied. Nine pituitaries from subjects whose death was unrelated to brain and endocrine diseases, were also studied as a control group in the PRL binding studies. MEASUREMENTS: Free PRL-R in microsomal membranes were determined by in-vitro radioreceptor assay using 125I-labelled human PRL as ligand. Total PRL-R were also measured in the same membrane fractions by removing endogenous PRL bound to its receptors using 4 M MgCl2. Serum PRL levels were also evaluated in all patients before surgery using an IRMA method. RESULTS: Specific binding values for PRL (free PRL-R) were 0.39 +/- 0.03% (range 0-1.96%) in the pituitary adenomas. These binding values were identical to those observed in normal pituitaries (0.38 +/- 0.07%, range 0.1-0.78%). Elevated PRL binding (1.25% and 1.96%) was found in two patients with PRL secreting adenomas and very high serum PRL levels (5768 and 11240 mU/I. No PRL binding was shown in 4 patients. Treatment of membranes with 4 M MgCl2 increased the specific binding (total PRL-R) in both pituitary tumours (0.5 +/- 0.11%; P < 0.001) and normal pituitaries (0.47 +/- 0.07%; P < 0.02). CONCLUSIONS: Our data have demonstrated the presence of prolactin receptors in normal cadaveric pituitary and in most pituitary adenomas, irrespective of histological classification. In particular, elevated prolactin receptor levels were shown in PRL-secreting tumours from patients with markedly increased serum PRL levels. Our study may support several lines of experimental evidence for a specific functional role for PRL in the growth of some pituitary adenomas.
Asunto(s)
Adenoma/química , Neoplasias Hipofisarias/química , Receptores de Prolactina/análisis , Adenoma/sangre , Adulto , Anciano , Femenino , Humanos , Inmunohistoquímica , Membranas Intracelulares/química , Cloruro de Magnesio/farmacología , Masculino , Microsomas/química , Persona de Mediana Edad , Hipófisis/química , Neoplasias Hipofisarias/sangre , Prolactina/sangre , Unión Proteica/efectos de los fármacos , Ensayo de Unión RadioliganteRESUMEN
Growth hormone secretagogues (GHSs) are synthetic peptidyl and nonpeptidyl molecules that possess strong growth hormone-releasing activity acting on specific pituitary and hypothalamic receptor subtypes. Differently from nonpeptidyl GHSs, peptidyl molecules such as hexarelin, a hexapeptide, possess specific high-affinity binding sites in animal and human heart and, after prolonged treatment, protect rats in vivo from ischemia-induced myocardial damage. To verify the hypothesis that peptidyl GHSs protect heart cells from cell death, we have investigated the cellular effects of hexarelin on H9c2 cardiomyocytes, a fetal cardiomyocyte-derived cell line, and on Hend, an endothelial cell line derived from transformed murine heart endothelium. We show that (i)H9c2 cardiomyocytes show specific binding for 125I-Tyr-Ala-hexarelin, which is inhibited by peptidyl GHSs such as Tyr-Ala-hexarelin and hexarelin but not by the nonpeptidyl GHS MK-0677, (ii) hexarelin promotes survival of H9c2 cardiomyocytes induced to die by doxorubicin, and (iii) that hexarelin inhibits apoptosis, as measured by DNA fragmentation, induced in both H9c2 myocytes and endothelial cells. In conclusion, our findings show that peptidyl GHSs such as hexarelin act as survival factors for cardiomyocytes and endothelium-derived cells in culture. These findings suggest that the inhibitory activity of hexarelin on cardiomyocytes and endothelial cell death could explain, at least partially, its cardioprotective effect against ischemia recorded in rats in vivo.
Asunto(s)
Doxorrubicina/antagonistas & inhibidores , Corazón/efectos de los fármacos , Oligopéptidos/farmacología , Animales , Muerte Celular , Línea Celular/efectos de los fármacos , Membrana Celular/metabolismo , Células Cultivadas/efectos de los fármacos , Fragmentación del ADN/efectos de los fármacos , Endotelio/efectos de los fármacos , Radioisótopos de Yodo , Isquemia Miocárdica/prevención & control , Unión Proteica , RatasRESUMEN
EP1572 UMV1843 [Aib-DTrp-DgTrp-CHO]) is a new peptido-mimetic GH secretagogue (GHS) showing binding potency to the GHS-receptor in animal and human tissues similar to that of ghrelin and peptidyl GHS. EP1572 induces marked GH increase after s.c. administration in neonatal rats. Preliminary data in 2 normal young men show that: 1) acute i.v. EP1572 administration (1.0 microg/kg) induces strong and selective increase of GH levels; 2) single oral EP1572 administration strongly and reproducibly increases GH levels even after a dose as low as 0.06 mg/kg. Thus, EP1572 is a new peptido-mimetic GHS with potent and selective GH-releasing activity.